Compare XRX & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XRX | RCEL |
|---|---|---|
| Founded | 1906 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 368.8M | 306.5M |
| IPO Year | 2019 | 2018 |
| Metric | XRX | RCEL |
|---|---|---|
| Price | $3.07 | $10.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | $2.50 | ★ $7.88 |
| AVG Volume (30 Days) | ★ 3.5M | 712.7K |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | ★ 6.31% | N/A |
| EPS Growth | 23.26 | ★ 27.20 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $117,000,000.00 | $71,610,000.00 |
| Revenue This Year | $8.96 | $17.17 |
| Revenue Next Year | N/A | $49.82 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.45 |
| 52 Week Low | $1.19 | $3.22 |
| 52 Week High | $4.27 | $10.77 |
| Indicator | XRX | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 55.41 | 77.22 |
| Support Level | $2.97 | $3.70 |
| Resistance Level | $3.17 | N/A |
| Average True Range (ATR) | 0.13 | 0.72 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 68.09 | 92.92 |
Xerox Holdings Corp is a workplace technology company, building and integrating services-led, software-enabled, workplace solutions for enterprises large and small. It provide advance document technology, services, software, and integrated IT infrastructure solutions for a range of customers including small and mid-sized businesses, large enterprises, governments and graphic communications providers, and for partners who serve them. Xerox serves customers globally in North America, Europe, Latin America, Brazil, Asia Pacific (APAC), the Middle East, Africa, and India.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.